Trials / Active Not Recruiting
Active Not RecruitingNCT05891847
Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia
Non-interventional Study of Patients With Plexiform Neurofibromas and Neurofibromatosis Type I Starting Selumetinib in Russia
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 3 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness, safety of selumetinib and patient's parameters of symptomatic inoperable PN NF1 in real clinical practice in Russia
Detailed description
This study will be non-interventional retrospective and prospective study. Assessment of parameters will be carried out as if a patient is treated in real-life clinical setting. The patients should be enrolled into this project after evaluation of eligibility criteria by an investigator 10 clinical sites. No additional procedures besides those already used in the routine clinical practice will be applied to the patients. Study population will consist of pediatric patients aged 3 years and older with NF1 and symptomatic inoperable PN who were prescribed with selumetinib
Conditions
Timeline
- Start date
- 2023-03-21
- Primary completion
- 2026-03-20
- Completion
- 2026-03-20
- First posted
- 2023-06-07
- Last updated
- 2025-06-10
Locations
5 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT05891847. Inclusion in this directory is not an endorsement.